Calif. Supreme Court Rules In Favor Of Glaxo, FDA On Prop 65 Warnings
This article was originally published in The Rose Sheet
Executive Summary
State regulations that conflict with FDA drug labeling are preempted by federal law, the California Supreme Court ruled April 15 in a case challenging the state's mandatory Prop 65 warning requirements for nicotine replacement therapy (NRT) products
You may also be interested in...
CTFA Weighs In As Prop 65 Amicus Brief Filed In Calif. Supreme Court
The Cosmetic, Toiletry and Fragrance Association amicus curiae brief in defense of nicotine-replacement therapy manufacturers involved in California Prop 65 litigation reflects the group's concern the labeling conflict involved could extend to other OTC drugs
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle